WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.

MLA

Sand, Andrea, et al. “WEE1 Inhibitor, AZD1775, Overcomes Trastuzumab Resistance by Targeting Cancer Stem-like Properties in HER2-Positive Breast Cancer.” Cancer Letters, vol. 472, Mar. 2020, pp. 119–31. EBSCOhost, https://doi.org/10.1016/j.canlet.2019.12.023.

APA

Sand, A., Piacsek, M., Donohoe, D. L., Duffin, A. T., Riddell, G. T., Sun, C., Tang, M., Rovin, R. A., Tjoe, J. A., & Yin, J. (2020). WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer. Cancer Letters, 472, 119–131. https://doi.org/10.1016/j.canlet.2019.12.023

Chicago

Sand, Andrea, Mitchel Piacsek, Deborah L. Donohoe, Aspen T. Duffin, Geoffrey T. Riddell, Chaoyang Sun, Ming Tang, Richard A. Rovin, Judy A. Tjoe, and Jun Yin. 2020. “WEE1 Inhibitor, AZD1775, Overcomes Trastuzumab Resistance by Targeting Cancer Stem-like Properties in HER2-Positive Breast Cancer.” Cancer Letters 472 (March): 119–31. doi:10.1016/j.canlet.2019.12.023.